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Abstract
Introduction Genetic abnormalities or mutations in
premalignant breast lesions may have a role in progression
toward malignancy or influence the behaviour of subsequent
disease. The A908G (Lys303→Arg) change in the gene
encoding oestrogen receptor-α (ER-α) creates a
hypersensitivity to oestradiol and would have significant
consequences if present in breast carcinoma, especially those
treated with endocrine therapy. We have therefore examined a
panel of endocrine-treated invasive carcinomas for the presence
of this mutation.
Methods Sequencing of control DNA was shown to detect
mutation present in as little as 15% of the starting material.
Enrichment for the mutation by using MboII restriction digestion
allowed the detection of mutant present at 1% or less. We
applied these techniques to genomic DNA and cDNA from 136
invasive breast carcinomas.
Results No evidence of the A908G mutation was found with
either technique. The incidence of this mutation in our panel of
tumours is therefore significantly less than previously reported.
Conclusion The fact that the mutation was not found leads us
to believe that this mutation is absent from most cells in invasive
carcinomas and furthermore that the major expression product
of the ER-α gene in cancers does not contain the K303R
mutation. It is therefore unlikely to influence the effectiveness of
endocrine treatment.
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Introduction
Most breast cancers overexpress oestrogen receptor-α
(ER-α), and this molecule is the major target of the anti-
estrogens, such as tamoxifen, used to treat the disease.
Not all patients respond to anti-oestrogen treatment and
many who do respond later relapse. The reasons for treat-
ment failure are still unclear. The suggestion that mutation
of ER-α might have a role in the formation of breast cancer
and subsequent response to treatment was raised by the
detection of a somatic A908G (Lys303→Arg; K303R)
mutation in the gene encoding ER-α. This mutation was
reported in a significant proportion of breast hyperplasia [1]
and also in the majority of invasive cancers and all metas-
tases tested [2,3]. The K303R ER-α variant apparently
exhibits a hypersensitivity to oestradiol [1], a characteristic
that might allow breast cancers to respond to much lower
levels of oestrogenic stimulation with a subsequent impact
on malignant progression and the effectiveness of anti-oes-
trogen treatment. This would be of particular importance in
post-menopausal women and in women receiving anti-oes-
trogen therapy. We have therefore studied a cohort of post-
menopausal, endocrine-treated breast cancers for the
presence of this mutation. Furthermore, because expres-
sion of the hypersensitive mutant would be required for
activity, we also examined mRNA.
The detection of mutations in breast cancers is not a trivial
task, owing in part to the heterogeneity of tumour tissue
and also to the reporting of false positive and false negative
results. Although microdissection allows the purity of
selected cellular populations to be enhanced, the sensitiv-
ity and specificity of standard DNA sequencing
approaches still limit our ability to assess mutation status
accurately. We now show that by performing a second
round of sequencing after enrichment for the mutation, we
were able to increase the sensitivity and specificity of our
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assay and apply it to invasive carcinomas without the need
for microdissection.
Methods
Determination of sensitivity for mutation detection
To confirm the sensitivity of this technique for detection of
the mutant allele in the presence of wild-type DNA, experi-
ments were performed with the use of mixtures of cloned
wild-type and mutant polymerase chain reaction (PCR)
products, generated with primers described by Fuqua and
colleagues [1] (ERmut1, 5'-CAA GCG CCA GAG AGA
TGA TG-3'; ERmut2, 5'-ACA AGG CAC TGA CCA TCT
GG-3').
Plasmid clones of PCR products with either an A or a G at
position 908 of ER-α were mixed in various ratios (100% to
0% mutant) and diluted to the equivalent of 1000 copies
per PCR reaction before being amplified and sequenced. A
two-stage PCR was performed on 2 µl of mixed DNA in the
20 µl first-round reaction (20 cycles) and 4 µl of first-round
product in the 40 µl second round (50 cycles). For each
PCR an initial 13 min 95°C denaturation step was followed
by cycles of 95°C for 30 s, 68°C for 60 s and a single 3 min
final extension at 72°C. Other PCR conditions were also
the same in both rounds: 0.2 mM dNTPs, each primer at
0.5 µM, 0.5 units of HotstarTaq DNA polymerase (Qiagen)
and 1× PCR Buffer (containing 1.5 mM MgCl2; Qiagen).
PCR products were sequenced (Fig. 1) by using primers
ERmut1 and ERmut2 and subjected to MboII digestion,
reamplification and further sequencing as described below.
Digestion with MboII and reamplification by PCR
The MboII restriction enzyme has a GAAGA recognition
site; this sequence is present at the K303R mutation with
the second A being mutated to G. Digestion with MboII can
therefore be used as an assay for the presence of mutation,
with non-digested DNA indicating mutation within the rec-
ognition site [4]. PCR product (5–10 µl) was digested in a
total volume of 20 µl including 1× Buffer2 (New England
Biolabs) and 5 units of MboII restriction enzyme (New Eng-
land Biolabs) by incubation at 37°C for 90 min. PCR prod-
ucts were separated by electrophoresis on gels containing
3% Seakem Agarose (Flowgen) and TAE buffer (40 mM
Tris-acetate, 1 mM EDTA, pH 7.6). Molecular mass markers
(φX174/HaeIII; Abgene) were included on each gel and
DNA was revealed by the inclusion of 0.5 µg/ml ethidium
bromide, scanning with a Molecular Dynamics Fluorimag-
erSI and analysis with ImageQuant version 4.1 software
(Molecular Dynamics). After digestion the non-mutant 158-
base-pair (bp) ERmut1–ERmut2 PCR product gives rise to
118-bp and 40-bp bands, detectable by agarose gel elec-
trophoresis (Fig. 2), whereas 158-bp PCR products con-
taining mutant remain undigested. Similarly ERADNA1–
ERADNA2 genomic DNA and ERARNA1–ERARNA2
cDNA PCR products give different patterns of digestion
products depending on the presence of a mutation affect-
ing the MboII recognition site.
Rather than relying on the detection of non-digested PCR
products by agarose gel electrophoresis, we further
increased the sensitivity and specificity of this assay by
sequencing amplified non-digested DNA after digestion.
PCR reamplification of non-digested DNA (20 cycles) was
performed as above for primers ERmut1 and ERmut2 with
2 µl of a 1:10 dilution of the restriction digest. Reamplified
PCR products were sequenced with ERmut1 primer. In all
cases with any evidence of a mutant G at the relevant posi-
tion, alternative PCR reactions were examined and reverse
sequencing with primer ERmut2 was performed, to rule out
PCR or sequencing anomalies.
ER-α PCR
For  ESR1  genomic DNA (RefSeq NM_000125) from
breast cancer cases, primers were designed that were spe-
cific for genomic DNA (because they included intronic
sequence) and that better allowed sequence determination
in both directions (ERADNA1, 5'-AAG TGG CCT GAA
Figure 1
Sample electrophoretograms of sequence data with and without  enrichment by digestion with MboII Sample electrophoretograms of sequence data with and without 
enrichment by digestion with MboII. The sequence of the region of 
interest is shown: coding residues 903–913 (residues 1195–1205 of 
ESR1; GenBank accession number M12674). The position of the 
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GTT TGT TA-3'; ERADNA2, 5'-CTT ACC TGG CAC CCT
CTT-3'). PCR reactions contained 1 ng of genomic DNA,
0.2 mM dNTPs, each primer at 1 µM, 0.5 units of Hotstar-
Taq DNA polymerase (Qiagen), 1× PCR Buffer (containing
1.5 mM MgCl2; Qiagen) and additional MgCl2 to a final
concentration of 2.5 mM. An initial 13 min 95°C denatura-
tion step was followed by 40 cycles of 94°C for 40 s, 60°C
for 40 s, 72°C for 60 s and a single 10 min final extension
at 72°C. The 609-bp genomic PCR product is digested by
MboII to give a 296-bp product, a 6-bp product and prod-
ucts of 130 and 177 bp; the last two of these fail to digest
if a mutation is present and instead result in a 307-bp prod-
uct that can be reamplified by ERmut1 and ERmut2.
For RNA analysis from breast cancer cases, reverse tran-
scription (RT) was performed in duplicate on 0.5 µg of RNA
in accordance with the manufacturer's instructions (Invitro-
gen), after a DNAaseI digestion step (Invitrogen). RT reac-
tions incorporated Superscript II Reverse Transcriptase
(Invitrogen), 0.5 µg of oligo (dT)17 and 0.5 µl of Prime
Recombinant Ribonuclease Inhibitor (Eppendorf). Parallel
reactions were performed in which the RT enzyme was
omitted; these acted as controls for genomic DNA contam-
ination. RT–PCR reactions were performed with cDNA-
specific primers designed to cross intron–exon boundaries
(ERARNA1, 5'-AAG TGG GAA TGA TGA AAG GT-3';
ERARNA2, 5'-CAA GAG CAA GTT AGG AGC AA-3') and
that better allowed sequence determination in both direc-
tions. These primers are located in exons 4 and 6 of ER-α
and generate a 491-bp RT–PCR product. The same prim-
ers occasionally amplify additional, minor, shorter products
arising from splice variants in which exon 5 is absent. PCR
reactions contained 2 µl of a 1:20 dilution of the RT reac-
tion, 0.2 mM dNTPs, each primer at 1 µM, 0.5 units of Hot-
starTaq DNA polymerase (Qiagen) and 1× PCR Buffer
(containing 1.5 mM MgCl2; Qiagen). PCR cycling condi-
tions were the same as for genomic DNA from breast can-
cers. The 491-bp genomic PCR product is digested by
MboII to give a 135-bp product, a 49-bp product and prod-
ucts of 130 bp and 177 bp; the last two of these fail to
digest if a mutation is present and instead result in a 307-
bp product that can be reamplified by ERmut1 and
ERmut2.
DNA sequencing
PCR products were treated with ExoSAP (Amersham Bio-
sciences) before sequencing. Fluorescent DNA sequenc-
ing (Fig. 1) was performed with DYEnamic ET Dye
Terminator Cycle Sequencing Kit for MegaBACE (Amer-
sham Biosciences) and analysed on a MegaBACE 1000
(Amersham Biosciences). For RT–PCR products, the prim-
ers used for PCR were also used for sequencing. When
sequencing the genomic DNA from breast cancers the
reverse primer ERADNA2 and an additional forward
sequencing primer (ERADNA3, 5'-TAC GAA AAG ACC
GAA GAG-3') were used. Primer ERADNA3 is located in
exon 5 of ER-α and overcomes difficulties in sequencing
through an A and T rich tract in intron 4 of ER-α; the same
primer can also be used to sequence RT–PCR products
and overcomes any difficulties caused by exon-5-deleted
PCR products. DNA sequencing of genomic and cDNA
PCR products was performed in both directions and the
position of the putative mutation was analysed individually
for each PCR product. To call a mutation we adopted the
standard practice that it should be observed in at least two
independent PCR reactions (avoiding possible PCR misin-
corporation due to Taq polymerase infidelity) and in both
sequencing directions (avoiding sequencing anomalies
due to misincorporation of dideoxy terminators).
Patients and samples
Post-menopausal patients undergoing treatment for inva-
sive breast cancer during the period between 1993 and
1999 were identified within the database of the Cancer Tis-
sue Bank Research Centre (CTBRC) at the Royal Liverpool
University Hospital. The diagnoses of invasive cancers
were made in accordance with the pathology guidelines of
the NHS Breast Screening Program [5].
DNA and/or RNA from 136 cases were selected for analy-
sis and provided by CTBRC along with further details as
given in Table 1. All tissue donated to CTBRC is fully con-
sented for research purposes and permission was granted
by all required local research ethics committees.
Results
Our ability to detect variable amounts of mutant 908G ER-
α in the presence of wild-type 908A ER-α was confirmed
by sequencing PCR products from mixtures of these two
variants (Fig. 1). Direct sequencing was routinely sensitive
enough to detect mutant ER-α when present in as little as
15% of the starting DNA and was frequently able to detect
the mutation at even lower levels (for example 10%). This
was true of sequencing in either direction, although for the
original primers described by Fuqua and colleagues [1] the
reverse sequence was more difficult to read because the
Figure 2
Agarose gel electrophoresis of control PCR products with and without  digestion with MboII Agarose gel electrophoresis of control PCR products with and without 
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mutation was closer to the reverse PCR primer (ERmut2).
The new primers designed for use on cDNA overcame this
limitation, while ensuring that only cDNA was amplified.
PCR primers for genomic DNA were similarly specific for
genomic DNA and, when used in conjunction with a
sequencing primer (ERADNA3), again gave sequence in
both directions.
Digestion with MboII restriction enzyme allowed the detec-
tion of as little as 1% mutant DNA by agarose gel electro-
phoresis in control reactions (Fig. 2). However, no evidence
of undigested PCR product was visible for any breast
tumour assayed in this way. When sequencing control
DNA reamplified with ERmut1 and ERmut2 after enrich-
ment for mutant DNA by MboII digestion (Fig. 1), the
mutant G base was clearly detected even when only
present in 1% of the original DNA. The wild-type A was also
detected, either because of inefficient digestion or because
of heterodimer formation in the PCR reaction. Notably in
control reactions containing only wild-type ER-α, any post-
digest reamplified DNA was clearly wild type. Therefore,
despite a failure to detect non-digested PCR product on
gels stained with ethidium bromide, reamplification and
sequencing confirms that restriction digestion is seldom
100% efficient and that by PCR we are able to reamplify
products originating from 1% or less of the starting DNA. It
is therefore possible to apply this reamplification and
sequencing technique to all samples, because the PCR
used routinely amplifies non-digested DNA enriched for
mutant PCR product.
The enhanced sensitivity after enrichment using digestion
with MboII and reamplification is not without drawbacks, in
that we detected a greater number of PCR and sequencing
anomalies with this technique. For non-enriched sequence
analysis, evidence of a very minor G in genomic DNA from
two breast cancers was subsequently shown to be due to
sequencing anomalies because they were not present
either in repeat PCR products from the same cases or in
sequence generated in the reverse direction. After enrich-
ment, similar errors were noted in eight genomic DNA PCR
products and six cDNA PCR products. Ten of these anom-
alies were apparently due to Taq polymerase infidelity (that
is, they were identified in reverse sequencing but not
repeatable in replicate PCR) and four were sequencing
anomalies (that is, they were not identifiable in reverse
sequencing). Notably, errors due to Taq polymerase infidel-
ity were seen only with the more sensitive assay based on
Table 1
Case selection
Parameter Detail Value
Age (years) Range 48–88
Histology Invasive ductal 115
Invasive lobular 11
Other 10
ER-α Positive 88
Negative 42
Grade 1 21
25 3
36 2
Nodal status Positive 51
Negative 62
Size <2 cm 55
≥ 2 cm 79
Stage 1 33
27 6
35
Tumour (%) ≥ 50 100
≥ 75 91
≥ 90 63
ER-α, oestrogen receptor-α.Available online http://breast-cancer-research.com/content/7/1/R113
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enrichment with MboII, and no such anomalies of either
type were seen in any non-mutant controls at the relevant
base position.
We were unable to confirm that the proposed ER-α A→G
mutation leading to a K303R amino acid substitution was
present in any case of invasive cancer examined. In all, we
examined 136 cases of invasive cancer (Table 1) with our
MboII-enriched sequencing assay, having also sequenced
130 of these before enrichment. With the exception of the
14 cases noted previously, in every sequenced PCR prod-
uct the A at the base position of the variant was clearly an
A with no evidence of any G substitution. For 60 of these
cases we examined both genomic DNA and cDNA, for 71
cases genomic DNA only was examined (for example, for
ER-α-negative cancers) and for 5 cases only cDNA was
examined. All 100 cases of invasive cancer for which a
pathologist assessed the proportion of tumour cells con-
tained at least 50% tumour, and 63% contained at least
90% tumour cells. Given the proven sensitivity of our tech-
niques we would therefore have expected to detect the
hypersensitive ER-α mutation even if present in only a
minority of cancer cells or contaminating normal cells.
Discussion
The abundant expression of ER-α in most breast cancers is
fundamental to both our understanding of this disease and
its treatment. The observations that ER-α is overexpressed
in a proportion of premalignant lesions [6,7] and is possibly
related to an increased risk of progression [8] further raise
the importance of oestrogenic activity in the establishment
and behaviour of breast carcinoma. It is therefore important
to understand whether other mechanisms for increased
ER-α activity are also present in breast tumours or their
putative precursors. One such mechanism is the hypersen-
sitivity apparently inferred by a K303R mutant ER-α
reported to be present in a significant proportion of breast
hyperplasia [1].
We have been unable to detect the reported A908G muta-
tion of ER-α in genomic DNA from any case of invasive car-
cinoma in our study, despite applying a sensitive and robust
assay capable of detecting mutant if present in as little as
1% of the starting DNA. The absence of this hypersensitive
ER-α variant suggests that this mutation is not present in
the majority of cells in such lesions, or indeed even in a sig-
nificant minority. Furthermore, the absence of the mutation
in RT–PCR products confirms that non-mutant ER-α is the
major expression product in the breast cancers. Zhang and
colleagues also failed to detect the mutation in a variety of
breast lesions from Japanese women [4], and while this
manuscript was under review two further papers have
reported a lack of evidence for the K303R mutation [9,10].
We have previously been unable to detect the mutation by
sequencing a series of 56 microdissected ductal carcino-
mas in situ from an unrelated cohort, confirming that this
mutation is also apparently absent from these premalignant
lesions.
Case selection can influence detection rates, and the
cohort of patients tested here was selected by virtue of
being post-menopausal and treated with endocrine thera-
pies but not chemotherapy, so as to allow any effect on
endocrine treatment to be more easily defined. Although it
is possible that the mutation occurs in other groups of
breast cancers, our cohort is broadly representative of sub-
groups defined by ER-α status, nodal status, grade, tumour
size and histology. Other studies reporting an inability to
detect the mutation [4,9,10] have applied no obvious
selection criteria and it therefore seems unlikely that any
selection bias is to blame for the lack of detectable
mutation.
The low level of risk of subsequent cancer attached to
hyperplasia implies that many of these lesions fail to con-
tribute to disease progression and it is perhaps therefore
unsurprising that a mutation so far reported in only about
one-third of hyperplasias by a single laboratory is found to
be absent from more advanced lesions in the present
study. Preliminary reports of the K303R mutation in a
higher proportion of breast cancers [2,3] from the same
group as reported the original observations in hyperplasia
are perplexing. Although confirmatory data have not so far
been published, these results continue to be reported at
scientific meetings and referenced in reviews [11]. Many
previous studies of mutation in breast cancers have failed
to report this mutation, and more recent reports [4,9,10]
have also produced evidence that if it exists it does so
below the level of detection of the techniques used. It is
therefore important to consider the sensitivity and specifi-
city of the different assays used to detect the K303R
mutant. The fact that Zhang and colleagues analysed 7
breast hyperplasias [4] and Tebbit and colleagues ana-
lysed 25 hyperplasias [9] and found no mutation rules out
the use of hyperplasia as 'positive' controls and challenges
the original observations.
Here the sequencing of PCR products with fluorescent
dideoxy terminators is shown to be sensitive enough to
detect a 908G mutant when present at 15% or less of the
starting DNA, in keeping with the results of Tebbit and col-
leagues [9]. This is probably suitable for use with microdis-
sected lesions as used by Tebbit and colleagues for 36
invasive cancers, or lesions with a relatively high tumour
content as used here (Table 1), but might not be sensitive
enough for use with non-microdissected cancers used
elsewhere [4,10] or if the mutation is present in only a small
minority of cancer cells. We therefore also used gel-based
PCR with restriction-fragment-length polymorphism and
were able to detect as little as 1% mutant by agarose gelBreast Cancer Research    Vol 7 No 1    Davies et al.
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electrophoresis of PCR products from control mixing
experiments. Although the same technique was used by
Zhang and colleagues for 215 cancers [4], they did not
report their detection sensitivity or confirm their specificity.
Given that this technique potentially detects very low levels
of mutation at any position in the MboII recognition site, it is
important to confirm sensitivity and specificity by a further
round of DNA sequencing. A very significant enhancement
of sequencing sensitivity (to 1% mutant or less) was seen
with this MboII digestion and reamplification technique. We
can therefore state that this mutation is not present in the
vast majority of tumour cells of any cancer tested, even
without the benefit of enrichment for tumour cells by
microdissection.
Although assay sensitivity is important, specificity is equally
crucial. We never reported any mutant in either assay used
for our non-mutant control DNA, indicating that our specif-
icity is high. However, in our experience, false positive
mutations by DNA sequencing, as seen here in 16 of the
136 cancers tested, are to be expected when PCR reac-
tions are performed on very low levels of DNA as found in
many microdissected samples, or after digestion with
restriction enzyme. It is therefore important to perform rig-
orous confirmatory assays. To this end, we always sought
to confirm mutations by sequencing in both directions to
avoid anomalies that often occur as a result of the misincor-
poration of dideoxy terminators in unidirectional sequenc-
ing. We also sequenced multiple PCR products to avoid
anomalies due to Taq polymerase infidelity. Originally, the
K303R mutation was reported in 34% of microdissected
hyperplasias tested by unidirectional, non-fluorescent
sequencing [1]. This assay is prone to false positives and it
is unclear whether replicate PCR or other confirmatory
assays were performed. The fact that the mutation was
always found in addition to the wild type is also to be
expected with artefacts due to dideoxy terminator misincor-
poration. The possibility that observations of the K303R
mutation in hyperplasia result from a lack of specificity must
therefore be considered and some doubt cast over other
positive results in cancers.
Conclusion
We have developed and validated a highly sensitive and
specific assay for the detection of the A908G (K303R)
mutation of ER-α. Having tested 136 different breast
tumours, we find no evidence to support the hypothesis
that the A908G mutation of ER-α is present or expressed
in breast carcinoma cells from post-menopausal, endo-
crine-treated patients. It is therefore unlikely to have an
impact on the effectiveness of such treatments.
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